Acute myeloblastic leukemia without maturation

Acute myeloblastic leukemia without maturation
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	Fatigue, pallor, easy bruising, bleeding, infections
Complications	Anemia, thrombocytopenia, neutropenia, leukostasis
Onset	Sudden
Duration	Variable
Types	N/A
Causes	Genetic mutations in myeloid progenitor cells
Risks	Radiation exposure, chemotherapy, benzene exposure, genetic predisposition
Diagnosis	Bone marrow biopsy, complete blood count, cytogenetic analysis
Differential diagnosis	Acute lymphoblastic leukemia, chronic myeloid leukemia, myelodysplastic syndrome
Prevention	N/A
Treatment	Chemotherapy, stem cell transplant
Medication	N/A
Prognosis	Variable, depends on cytogenetic profile and response to treatment
Frequency	Rare
Deaths	N/A

A subtype of acute myeloid leukemia

Acute myeloblastic leukemia without maturation (AML-M1) is a subtype of acute myeloid leukemia (AML), a cancer of the blood and bone marrow characterized by the rapid growth of abnormal myeloblasts. In AML-M1, there is minimal maturation of the myeloblasts, and the bone marrow is predominantly composed of these immature cells.

Pathophysiology

AML-M1 is characterized by the proliferation of myeloblasts that fail to differentiate into mature white blood cells. This results in the accumulation of immature cells in the bone marrow and peripheral blood, leading to anemia, thrombocytopenia, and neutropenia. The lack of maturation in AML-M1 distinguishes it from other subtypes of AML where some degree of maturation is observed.

Clinical Presentation

Patients with AML-M1 typically present with symptoms related to bone marrow failure, such as fatigue, pallor, bleeding, and increased susceptibility to infections. The rapid proliferation of myeloblasts can also lead to leukostasis, a condition where the high number of leukemic cells causes blood flow disturbances.

Diagnosis

The diagnosis of AML-M1 is made through a combination of blood tests, bone marrow biopsy, and cytogenetic analysis. The bone marrow examination reveals a high percentage of myeloblasts with minimal maturation. Flow cytometry and immunophenotyping are used to confirm the diagnosis and to differentiate AML-M1 from other hematological disorders.

Treatment

The treatment of AML-M1 involves chemotherapy to induce remission, followed by consolidation therapy to eliminate residual disease. The standard induction regimen includes cytarabine and an anthracycline. In some cases, hematopoietic stem cell transplantation may be considered, especially for patients with high-risk features or those who relapse.

Prognosis

The prognosis of AML-M1 depends on various factors, including the patient's age, overall health, cytogenetic abnormalities, and response to initial treatment. Younger patients with favorable cytogenetic profiles tend to have better outcomes.

Related pages

• Acute myeloid leukemia
• Myeloblast
• Bone marrow
• Chemotherapy